MiNK Therapeutics Reports $0.2M in Revenue and $2.6M Q3 Net Loss

MiNK Therapeutics reported $0.2 million in first pre-commercial product revenue and a net loss of $2.6 million for the third quarter of 2026. Net loss per share was $0.50, compared with $0.65 a year earlier. The company said its randomized Phase 2 ARDS trial of agenT-797 continued enrolling, with U…